- Home
- LLY
as 08-25-2025 4:00pm EST
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
| Founded: | 1876 | Country: | United States |
| Employees: | N/A | City: | INDIANAPOLIS |
| Market Cap: | 684.4B | IPO Year: | N/A |
| Target Price: | $975.20 | AVG Volume (30 days): | 7.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 15 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 15.29 | EPS Growth: | 88.31 |
| 52 Week Low/High: | $623.78 - $972.48 | Next Earning Date: | 08-07-2025 |
| Revenue: | $53,258,100,000 | Revenue Growth: | 36.83% |
| Revenue Growth (this year): | 34.53% | Revenue Growth (next year): | 19.44% |
Latest Eli Lilly and Company News
LLY Breaking Stock News: Dive into LLY Ticker-Specific Updates for Smart Investing
PR Newswire
a day ago
Lilly to participate in Morgan Stanley 23rd Annual Global Healthcare Conference
MT Newswires
a day ago
Immuneering Partners With Eli Lilly for Lung Cancer Drug Trials
GlobeNewswire
a day ago
Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib
GlobeNewswire
a day ago
Incyclix Bio Secures $11.25 Million Series B Extension to Advance the Phase 1/2 Clinical Trial of INX-315 in Patients with CDK4/6 Inhibitor Resistant ER+/HER2- Breast Cancer or CCNE1-Amplified Solid Tumors
Insider Monkey
a day ago
Eli Lilly (LLY) Launches Easy Mounjaro Pen in India Amid Growing Diabetes Market
Motley Fool
2 days ago
The Best Stocks to Invest $50,000 in Right Now
Bloomberg
3 days ago
Credit Fuels the AI Boom — and Fears of a Bubble
Investor's Business Daily
4 days ago
Drug Tariffs Finally Land. Why Pharma Stocks Are Breathing Easy.
Compare LLY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LLY Eli Lilly and Company - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.